Global proteomic determination of the poly-pharmacological effects of PARP inhibitors following treatment of high-grade serous ovarian cancer cells

Global proteome perturbations upon PARPi treatment were measured using quantitative mass spectrometry-based proteomics. High-grade serous ovarian cancer (HGSOC) cell lines (PEO1, Caov3, and COV362) were treated with IC50 dose concentrations of Olaparib, Niraparib, and Rucaparub to assess differences in proteome response to differing PARPi accross a HGSOC cell line panel.